BioVersys Wins up to $8.92 Million from CARB-X to Develop Anti-Microbial Resistance Drugs
29.10.2019
CARB-X awards BioVersys as much as $8.92 million to support the development of first-in-class anti-virulence small molecule drugs that disarm bacteria, opening the door for a paradigm shift in AMR therapy. We interviewed CEO Marc Gitzinger.
 BioVersys CEO Marc Gitzinger
|
 |
BioVersys will receive $3.94 million in non-dilutive funding from CARB-X, with $4.98 million more possible based on project milestones. This funding will enable Basel-based BioVersys to accelerate development of new drugs designed to disarm bacteria, such as Staphylococcus aureus of its virulence determinants and toxins that cause serious skin infections spreading to muscles, and lungs.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) a global non-profit partnership led by Boston University, is dedicated to accelerating the early development of antibacterial R&D to address the rising global threat of drug-resistant bacteria.
BioVersys CEO Marc Gitzinger shares his entrepreneurial path and vision in our interview.
You won Venture Kick in 2008. How did it help lay the foundation for your growth and today's achievement?
Winning Venture Kick happened so early in BioVersys' history, 2.5 years before we actually went out to investors for the first time, so one can really say that Venture Kick started this company. The involved coaching, prize money and contacts gained through Venture Kick made everything else possible.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) a global non-profit partnership led by Boston University, is dedicated to accelerating the early development of antibacterial R&D to address the rising global threat of drug-resistant bacteria.
BioVersys CEO Marc Gitzinger shares his entrepreneurial path and vision in our interview.
You won Venture Kick in 2008. How did it help lay the foundation for your growth and today's achievement?
Winning Venture Kick happened so early in BioVersys' history, 2.5 years before we actually went out to investors for the first time, so one can really say that Venture Kick started this company. The involved coaching, prize money and contacts gained through Venture Kick made everything else possible.